Mirxes Holding Company Ltd. (Singapore)

The Company was incoporate in Cayman Islands on November 17, 2020. The Company is an investment holding company and principally engaged in developing and commercializing accurate, non-invasive and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. The company listing on the Main Board of the Stock Exchange and the date expected to be on or about Friday, May 23, 2025 with stockex number : 2629.
The Company is an investment holding company and principally engaged in developing and commercializing accurate, non-invasive and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases.
HISTORY :
2014 • MiRXES Singapore was established in Singapore by The Company co founders
• The Company were granted the know-how relating to the mSMRT-qPCR
assay and design service by Dr. Too, Dr. Zhou and Dr. Zou
• miRNA qPCR assays and reagents were launched for research use
2015 • The Company completed the construction of The Company manufacturing facilities in
Singapore
2016 • The Company started prospective study for clinical validation of
GASTROClear
2017 • The Company obtained CE-IVD Mark for GASTROClearTM
2018 • MiRXES Lab was established in Singapore
• The Company started strategic collaboration with Johnson Johnson
Innovation and Janssen Pharmaceutica NV to develop a novel
circulating miRNA diagnostic test, with the aim to improve the
detection of early-stage lung cancer
2019 • The Company obtained approval from HSA for GASTROClearTM and began
its commercialization in Singapore
• The Company initiated a clinical study of GASTROClearTM in Japan in
November 2019
2020 • The Company commenced The Company infectious diseases business segment
2021 • Registrational clinical trials for GASTROClearTM were launched
in the PRC
• The Company completed Series C Financing (as defined below) and raised an
aggregate amount of US 87 million
2022 • LUNGClearTM was launched as LDT service
• The PHinder kit received the CE-IVD Mark
2023 • The Company obtained joint clinical diagnostics laboratory licenses with the
National University Hospital of Singapore in April 2023
• The Food and Drug Administration of the U.S. granted
GASTROClearTM Breakthrough Device Designation in May 2023
• The Company completed Series D Financing (as defined below) and raised an
aggregate amount of US 50 million
• The Company submitted a registration application to the NMPA for
GASTROClearTM in China
2024 • The Company obtained approval for GASTROClearTM and launched
GASTROClearTM as an IVD product in Thailand
• The Company received the Enterprise Development Grant from the Enterprise
Singapore Board for Indonesia expansion